Ethyreal Bio Launches With $101 Million to Advance Dual-Targeting TSHR Antibody for Graves' Disease and Thyroid Eye Disease
核心洞察
Ethyreal Bio (搜索) emerged from stealth with $101 million in Series A and B financing to develop ETHY-001 (搜索), a monoclonal antibody targeting the TSHR (搜索) receptor shared by Graves' disease (搜索) and thyroid eye disease (搜索).
ETHY-001 (搜索) is designed as a subcutaneous injection with half-life extension technology for infrequent dosing, potentially offering a patient-friendly alternative to existing intravenous therapies.
First-in-human clinical trials are expected to begin in the second half of 2026, with preclinical data to be presented at ENDO 2026 on June 15.
Ethyreal Bio (搜索), a Cambridge, Massachusetts-based biotechnology company, launched publicly on Wednesday with $101 million in financing to advance ETHY-001 (搜索), a monoclonal antibody designed to target the shared pathogenic driver of Graves' disease (搜索) (GD) and thyroid eye disease (搜索) (TED). The financing was structured as separate Series A and Series B rounds: the Series A was co-led by Atlas Venture (搜索) and Medicxi Ventures (搜索), alongside Nandi Life Sciences and Checkpoint Capital, while the Series B was led by Avoro Capital (搜索) and included all Series A investors.
ETHY-001 (搜索) is an antagonist monoclonal antibody targeting the thyroid stimulating hormone receptor (TSHR (搜索)), which is overactivated by pathogenic autoantibodies in both GD and TED. By blocking autoantibody-mediated TSHR activation, the therapy is designed to halt disease activity at its source. The drug is formulated for low-volume subcutaneous administration, with plans for an autoinjector, and incorporates half-life extension technology to enable infrequent dosing.
"GD and TED are prevalent and debilitating conditions with a shared causal driver — pathogenic stimulating autoantibodies to the TSHR (搜索)," said Niranjan Kameswaran, Ph.D., Chief Executive Officer of Ethyreal Bio (搜索). "These two conditions frequently co-exist in the same individual, yet current treatments for GD do not treat or prevent TED, and conversely, TED treatments do not address the hyperthyroidism characteristic of GD. By blocking autoantibody activation of the TSHR, ETHY-001 (搜索) is designed to target the underlying cause of disease and has the potential to address both conditions through a single, mechanism-driven therapy."
Disease Background and Unmet Need
Graves' disease (搜索) is the most common cause of hyperthyroidism, affecting approximately 1-2% of the adult population. The condition is driven by pathogenic autoantibodies that activate TSHR (搜索), leading to excess thyroid hormone production and significant systemic consequences, including cardiovascular, neurological, and metabolic complications. Approximately half of patients with GD develop thyroid eye disease (搜索).
Thyroid eye disease (搜索) is a serious, disfiguring, and potentially vision-threatening manifestation that arises when pathogenic autoantibody-mediated TSHR (搜索) activation occurs within the orbit of the eye. Most patients with TED have coexisting hyperthyroidism due to GD. TED can cause inflammation, proptosis, pain, diplopia, and in severe cases, permanent vision loss.
Current treatment options for GD do not address the underlying cause, are associated with high rates of relapse, and carry risks of serious side effects. Many patients eventually undergo permanent thyroid removal. Existing therapies do not treat or prevent TED. Treatment options for TED remain limited and may be associated with burdensome systemic side effects including hyperglycemia and risk of hearing loss, as well as risk of relapse.
Competitive Landscape
TED has become a competitive area of drug research in recent years. The current treatment standard is Tepezza, an intravenous drug Amgen acquired through a large acquisition. Amgen is developing an injectable version of Tepezza, and other companies such as Viridian Therapeutics are advancing new alternatives. However, those therapies only target TED and do not address Graves' disease (搜索).
"ETHY-001 (搜索)'s differentiated profile is unique in its potential to address two closely related, debilitating conditions," said Simon Read, Ph.D., Chairman of the Board. "The Company has made rapid progress and is supported by a healthy capital position. We have strong conviction in Ethyreal's ability to execute with focus and urgency and to establish itself as the leading company in GD and TED."
Upcoming Milestones
Ethyreal plans to initiate first-in-human clinical trials in the second half of 2026. Preclinical data on ETHY-001 (搜索) will be presented in an oral presentation at the Endocrine Society's 2026 Annual Meeting (ENDO 2026) in Chicago on June 15, 2026. The presentation, titled "ETHY-001, a Half-Life Extended, TSHR (搜索) Monoclonal Antibody Antagonist, Potently Inhibits TSHR Activation Induced by Patient Sera and M22-Induced Hyaluronan and IL-6 Secretion from TED Patient-Derived Orbital Fibroblasts," will be delivered by Kelly Foster, Ph.D., SVP of Translational Medicine at Ethyreal Bio (搜索).
Leadership and Governance
Ethyreal is led by CEO Niranjan Kameswaran, Ph.D., alongside Chief Development Officer Jessica Stromme, SVP Translational Medicine Kelly Foster, Ph.D., and SVP Clinical Development Stephen Huang, M.D. The Board of Directors includes Chairman Simon Read, Ph.D., Mark Chin of Avoro Ventures, Michael Gladstone and Jernej Godec, Ph.D. of Atlas Venture (搜索), Karen Smith, M.D., Ph.D., M.B.A., L.L.M., and Nick Williams, M.Pharm, Ph.D. of Medicxi Ventures (搜索).
"Ethyreal has assembled an accomplished management team and seasoned Board of Directors with the scientific, clinical and company-building experience needed to translate compelling biology into transformative medicines," said Read.